Jyong Biotech Plans Potential Texas Manufacturing Facility And U.S. Operations Center To Support Future Commercialization Of Drug Candidates

Jyong Biotech Ltd. (NASDAQ: MENS) plans to establish a new manufacturing facility and U.S. operations center in Texas to support its future commercialization of investigational drug candidates. The decision was influenced by factors such as competitive land costs, favorable corporate tax structure, and manufacturing incentives. The company has submitted a facility and operations plan to local authorities and is preparing to engage with government agencies regarding the necessary procedures.